Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine versus midazolam for prevention of acute kidney injury after traumatic shock
IRCT20250809066790N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dexmedetomidine and midazolam in acute kidney failure (AKF) (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoint: Incidence of acute kidney injury within the first 7 days of ICU admission. Started Nov 2025; status: completed.
02
Drugs
dexmedetomidinemidazolam
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20250809066790N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250809066790N1.